Urinary Potassium Excretion Tied to Renal, Cardio Risk in T2DM

This article originally appeared here.
Share this content:
Urinary Potassium Excretion Tied to Renal, Cardio Risk in T2DM
Urinary Potassium Excretion Tied to Renal, Cardio Risk in T2DM

FRIDAY, Nov. 13, 2015 (HealthDay News) -- For patients with type 2 diabetes, higher urinary potassium excretion is associated with decreased risk of renal and cardiovascular events, according to a study published online Nov. 12 in the Clinical Journal of the American Society of Nephrology.

Shin-ichi Araki, M.D., Ph.D., from the Shiga University of Medical Science in Otsu, Japan, and colleagues examined the correlation of urinary potassium and sodium excretion with the incidence of renal failure and cardiovascular disease in 623 patients with type 2 diabetes. Patients were enrolled between 1996 and 2003 and followed for a median period of 11 years.

The researchers found that 134 primary end points occurred during follow-up. Higher urinary potassium excretion, but not sodium excretion, correlated with lower risk of the primary end point of renal and cardiovascular events (renal replacement therapy, myocardial infarction, angina pectoris, stroke, and peripheral vascular disease). Compared with the lower quartile, the third and fourth quartile of urinary potassium excretion had adjusted hazard ratios of 0.56 and 0.33, respectively, for the primary end point. Correlations were similar for secondary renal end points. The annual decline rate in estimated glomerular filtration rate was significantly slower in the fourth quartile of urinary potassium excretion versus the first quartile.

"Higher urinary potassium excretion was associated with the slower decline of renal function and the lower incidence of cardiovascular complications in type 2 diabetic patients with normal renal function," the authors write.

The study was partially funded by grants from AstraZeneca and MSD.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths